10.1038/s41591-021-01544-x - A phase 1/2 trial of an immune-modula...

This document has been corrected

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

10.1038/s41591-021-01544-x

Published Online: 2021-12-?

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC

Authors: Ayako Wakatsuki Pedersen•Cathrine Lund Lorentzen•Cecilie Oelvang Madsen•Eva Ehrnrooth•Eva Ellebaek•Evelina Martinenaite•Helle Westergren Hendel•Inge Marie Svane•Julie Westerlin Kjeldsen•Mads Hald Andersen•Mai-Britt Zocca•Marco Donia•Morten Orebo Holmström•Rikke Boedker Holmstroem•Shamaila Munir Ahmed•Stine Emilie Weis-Banke•Tobias Wirenfeldt Klausen

This document has been corrected

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

10.1038/s41591-021-01544-x

Published Online: 2021-12-?

Journal: Nature Medicine

NOW

2022-03-08•Correction

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

10.1038/s41591-022-01771-w

* information provided by CrossRef

2022-03-08•Correction

10.1038/s41591-022-01771-w

* information provided by CrossRef

2021-12-?•Published

2022-03-08•Correction

Author Correction: A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

10.1038/s41591-022-01771-w

* information provided by CrossRef

This document has been corrected

A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

10.1038/s41591-021-01544-x

Published Online: 2021-12-?

Journal: Nature Medicine•Publisher: Springer Science and Business Media LLC